Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2013 May 1;11(5):531-46.
doi: 10.6004/jnccn.2013.0070.

Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines

Jaffer A Ajani  1 , David J Bentrem, Stephen Besh, Thomas A D'Amico, Prajnan Das, Crystal Denlinger, Marwan G Fakih, Charles S Fuchs, Hans Gerdes, Robert E Glasgow, James A Hayman, Wayne L Hofstetter, David H Ilson, Rajesh N Keswani, Lawrence R Kleinberg, W Michael Korn, A Craig Lockhart, Kenneth Meredith, Mary F Mulcahy, Mark B Orringer, James A Posey, Aaron R Sasson, Walter J Scott, Vivian E Strong, Thomas K Varghese Jr, Graham Warren, Mary Kay Washington, Christopher Willett, Cameron D Wright, Nicole R McMillian, Hema Sundar; National Comprehensive Cancer Network
Affiliations
Practice Guideline

Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines

Jaffer A Ajani et al. J Natl Compr Canc Netw. .

Abstract

The NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer provide evidence- and consensus-based recommendations for a multidisciplinary approach for the management of patients with gastric cancer. For patients with resectable locoregional cancer, the guidelines recommend gastrectomy with a D1+ or a modified D2 lymph node dissection (performed by experienced surgeons in high-volume centers). Postoperative chemoradiation is the preferred option after complete gastric resection for patients with T3-T4 tumors and node-positive T1-T2 tumors. Postoperative chemotherapy is included as an option after a modified D2 lymph node dissection for this group of patients. Trastuzumab with chemotherapy is recommended as first-line therapy for patients with HER2-positive advanced or metastatic cancer, confirmed by immunohistochemistry and, if needed, by fluorescence in situ hybridization for IHC 2+.

PubMed Disclaimer

Publication types

Substances